Jun 15, 2022 / 10:20PM GMT
Madhu Sudhan Kumar - Goldman Sachs Group, Inc., Research Division - Research Analyst
All right, everyone. Thank you for joining us today at Goldman Sachs Global Healthcare Conference. Really excited to be joined by the team from Iovance Biotherapeutics. Great to be here and let's just get started.
All right. So let's start with kind of top of the mind on your lead program, your tumor-infiltrating lymphocyte, or TIL drug, lifileucel, in the upcoming BLA submission in post-PD-1 melanoma. So kind of proximal question, how are things proceeding? And really, what is the cadence of events between now and the BLA submission in August?
Questions and Answers:
Jean-Marc Bellemin - Iovance Biotherapeutics, Inc. - CFO & Principal Accounting OfficerSo let me take this one. Thank you, Madhu and thanks for the invite. Obviously, it's nice to be in person. So we're on track. I mean let's go short. We are on track to submit the BLA in August after pre-BLA meeting with the FDA in July, as we previously communicated. As you have seen last
Trustpilot
